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Background. Low retention on combination antiretroviral therapy (cART) has emerged as a threat to the Joint United Nations 
Programme on human immunodeficiency virus (HIV)/AIDS (UNAIDS) 90-90-90 targets. We examined outcomes of patients who 
started cART but were subsequently lost to follow-up (LTFU) in African treatment programs.
Methods. This was a systematic review and individual patient data meta-analysis of studies that traced patients who were LTFU. 
Outcomes were analyzed using cumulative incidence functions and proportional hazards models for the competing risks of (i) death, 
(ii) alive but stopped cART, (iii) silent transfer to other clinics, and (iv) retention on cART.
Results. Nine studies contributed data on 7377 patients who started cART and were subsequently LTFU in sub-Saharan Africa. 
The median CD4 count at the start of cART was 129 cells/μL. At 4 years after the last clinic visit, 21.8% (95% confidence interval [CI], 
20.8%–22.7%) were known to have died, 22.6% (95% CI, 21.6%–23.6%) were alive but had stopped cART, 14.8% (95% CI, 14.0%–
15.6%) had transferred to another clinic, 9.2% (95% CI, 8.5%–9.8%) were retained on cART, and 31.6% (95% CI, 30.6%–32.7%) 
could not been found. Mortality was associated with male sex, more advanced disease, and shorter cART duration; stopping cART 
with less advanced disease andlonger cART duration; and silent transfer with female sex and less advanced disease.
Conclusions. Mortality in patients LTFU must be considered for unbiased assessments of program outcomes and UNAIDS 
targets in sub-Saharan Africa. Immediate start of cART and early tracing of patients LTFU should be priorities.
Keywords. HIV; antiretroviral therapy; loss to follow-up; mortality; sub-Saharan Africa.
Much progress has been made over the past 10 years with scaling 
up combination antiretroviral therapy (cART) in resource-lim-
ited settings: by July 2017, >20.9 million people were receiving 
cART [1]. Retention in care and adherence to cART are cru-
cial for viral suppression and, therefore, for preventing human 
 immunodeficiency virus (HIV)–related morbidity/mortality, 
HIV drug resistance, and onward transmission. Treatment 
programs’ effectiveness is therefore key for reaching the global 
90-90-90 targets to end HIV/AIDS [2]. As documented repeat-
edly in systematic reviews of the literature, programs’  retention 
of HIV patients in resource-limited settings is a matter of 
concern; substantial proportions of patients are lost to follow-up 
(LTFU), particularly in the first year of cART [3–7].
Ignoring patients with LTFU undermines overall retention 
and underestimates program-level mortality as mortality is 
higher among patients LTFU [8–10]. In recent years, interest 
has grown in tracing patients LTFU to ascertain their vital and 
treatment status, and to bring patients back to care. We recently 
conducted a systematic review and meta-analysis of tracing 
studies of HIV-infected patients LTFU after starting cART 
in sub-Saharan Africa [11]. We found that mortality among 
patients LTFU had declined in more recent years, whereas 
undocumented (silent) transfer and treatment interruption 
increased. The previous study [11] was based on published 
aggregate data, which precluded analyses of the time to out-
comes and the identification of the patient characteristics asso-
ciated with different outcomes.
The present study extends the earlier work by analyzing indi-
vidual patient data (IPD) from tracing studies identified in the 
systematic review. We estimated the cumulative incidence of 
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death, stopping of cART, silent transfer to another care provider, 
and retention in care on cART, and examined factors associated 
with mortality and other tracing outcomes.
METHODS
Identification of Eligible Studies
The literature search and inclusion criteria are described in de-
tail elsewhere [11]. In brief, we searched 3 databases (PubMed, 
Embase, and Latin American & Caribbean Health Sciences 
Literature) to identify eligible studies in sub-Saharan Africa pub-
lished from 1 January 2009 to 31 December 2015. Studies where 
patients who started cART for their own health (adults or chil-
dren fulfilling respective criteria of lifelong cART) were LTFU 
and then actively traced to establish their vital status were eligible. 
We excluded studies in tuberculosis patients and those focusing 
on prevention of mother-to-child transmission programs or post-
exposure prophylaxis. For the current study, we also excluded 
studies from South Africa that linked clinical databases with civil 
registry to identify deaths because only data on mortality but 
no other outcome were collected in these studies. The search of 
the bibliographic databases was complemented by reviewing the 
abstracts of the Conference on Retroviruses and Opportunistic 
Infections (2014–2015); the Conference on HIV Pathogenesis 
and Treatment of the International AIDS Society (2009–2015), 
and the International AIDS Conference (2010–2014).
Request for Individual Patient Data
We contacted the authors of the 24 eligible studies [12–35] 
identified in the systematic review [11]. The data from abstracts 
were generally too sparse to determine eligibility, but abstract 
authors were also asked to contribute individual-level data, in-
cluding patient characteristics (sex, date of birth, clinical stage 
at cART initiation, date of cART initiation, date of last contact), 
laboratory data (CD4 cell count at cART initiation), and trac-
ing outcomes with their dates of occurrence and ascertainment. 
Eligibility was determined based on the data received. The data 
were cleaned in collaboration with the original investigators.
Statistical Analysis
The studies considered a patient as LTFU if he or she did 
not return within 2 weeks to 3  months after the next sched-
uled appointment. Tracing outcomes were classified as “died,” 
“stopped cART” (ie, found alive but stopped cART), “trans-
ferred to other clinic,” “retained on cART” (found alive without 
having been transferred nor stopped cART), and “not found.” 
The group retained on cART includes patients erroneously clas-
sified as LTFU and intermittent attenders who came back to the 
clinic after a “treatment gap.” In the analysis, we considered all 
patients as being LFTU right after their last clinic visit and we 
defined time to event as the time between the last clinic visit and 
the date of the occurrence of the event (if available) or the date 
of its ascertainment (otherwise). We calculated nonparametric 
cumulative incidence functions to describe the probability of an 
outcome over time in the presence of the competing risks.
Subdistribution hazard models [36] were fitted to assess the 
association of patient characteristics with the different tracing 
outcomes. These models estimate the association of covariates 
on the cumulative incidence of an outcome, while accounting 
for competing events. We stratified our models to account for 
cohort heterogeneity by allowing cohort-specific baseline haz-
ards [37]. The following patient characteristics were included 
as model covariates at the time of cART initiation: sex, World 
Health Organization (WHO) clinical stage (I–II, III, IV), and 
CD4 cell count (<50, 50–99, and ≥100 cells/µL). In addition, we 
included the calendar period (before 2009 and 2009 or later), age 
(<16, 16–29, 30–39, and ≥40 years) and the time on cART (<1, 
1–2, and ≥2 years) at the last clinic visit. Missing WHO stage, 
CD4 cell counts, age, and time on cART were estimated through 
multiple imputations using a modified approach suitable for the 
subdistribution hazards model [38]. We imputed 20 datasets 
and pooled model parameter estimates using Rubin rules [39]. 
Sensitivity to imputation was assessed by comparing parameter 
estimates of models fitted on the imputed dataset with models 
fitted on the complete cases [40]. We assessed model fit using 
the Akaike information criterion and proportionality of hazards 
by inspecting model residuals against failure time and explored 
interactions between model covariates. We used a random inter-
cept logistic regression model to examine the influence of the 
period between loss to follow-up and ascertainment of outcomes 
on the probability of remaining LTFU (outcome “not found”).
We compared the characteristics of published studies that 
provided IPD data with the studies that did not. Furthermore, 
we used random intercept logistic meta-regression models to 
compare mortality, transfer to another clinic, and stop cART 
estimates published in the respective articles between studies 
included and not included in the IPD meta-analysis.
For cohorts that provided data on both patients retained in 
care and patients LTFU, we calculated nonparametric cumula-
tive incidence functions for the 2 groups separately to compare 
their mortality after the start of cART (again accounting for the 
presence of competing risks). Finally, we repeated analyses ex-
cluding a large study from Lilongwe, Malawi [25].
All analyses were carried out using R statistical software (ver-
sion 3.3.2) [41], including the packages “mstate” for cumulative 
incidence analysis, “crrSC” for stratified subdistribution hazard 
modeling, and “smcfcs” for multiple imputation. Results are 
shown as cumulative probabilities or subdistribution hazard 
ratios with 95% confidence intervals (CIs).
RESULTS
The authors of 22 of the 24 eligible articles responded by elec-
tronic mail or phone. In addition, 24 authors of potentially eligible 
abstracts were contacted (Figure 1). Seven authors of published ar-
ticles [12–14, 21–25] and 2 abstract [42–43] authors provided data 
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on 7377 patients who started cART in a treatment program in 1 
of 8 countries in East Africa (Kenya, Tanzania, Uganda), Southern 
Africa (Malawi, Mozambique, Zambia, Zimbabwe), or Central 
Africa (Cameroon) and were later LTFU and traced. All sites were 
involved in the routine treatment and care of HIV-infected patients.
Sociodemographic and clinical features of patients, together 
with cohort characteristics, are summarized in Table  1. One 
study included adults and children [13], 1 study included chil-
dren only [24], and 6 studies included adults aged ≥16  years 
only. Overall, patients’ median age at last clinic visit was 
34  years (interquartile range [IQR], 28–41  years) and 4148 
of 7377 patients (56.2%) were female. The median CD4 cell 
count at cART initiation was 129 cells/µL (IQR, 54–216 cells/
µL); most patients were in WHO clinical stage III or IV (5090 
[69.0%]). CD4 cell counts were missing for 2987 patients 
(40.5%) and 1448 patients (19.6%) had a missing WHO clinical 
stage. The majority of patients were lost in the first 6 months 
after cART initiation: the median time on cART was 162 days 
overall; it ranged from 35 days in the study from Zimbabwe [42] 
to 328 days in the study from Kenya [13] (Table 1).
All programs traced patients by home visits, or by phone calls 
and home visits. The median number of days from LTFU to 
tracing ranged from 82 days in the study from Cameroon [21] 
to 588 days in Kenya [13], and was 327 days overall (Table 2). 
A  total of 1606 (21.8%) deaths were identified; 1667 (22.6%) 
individuals were found to be alive but had stopped cART; 1094 
(14.8%) had transferred to another clinic, and 2119 (28.7%) 
could not be found (Table  2). For outcome death, the date 
of death was available in most cases (in 1516 of 1608 deaths 
[94.3%]). For outcomes stopping cART and transfer to another 
clinic, the exact date the outcome occurred was generally una-
vailable and the date of ascertainment was used instead in 1673 
of 1683 (99.4%) for stopping cART and in 966 of 1098 (88.0%) 
for silent transfer. In logistic regression, a longer delay between 
loss to follow-up and tracing was associated with an increase in 
the probability of the patient remaining LTFU (outcome “not 
found”). The odds ratio (OR) per standard deviation increase 
in the number of days between LTFU and tracing was 2.05 
(95% CI, 1.95–2.15). The probability of the other outcomes was 
reduced accordingly.
Figure 1. Flow of identifying eligible studies that contributed individual patient data.
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Figure  2 shows the cumulative incidence functions for 
each tracing outcome stacked on top of each other, together 
with a table showing point estimates and 95% CIs at 1, 2, 3, 
and 4  years after the last clinic visit. Four years after the last 
clinic visit, an estimated 21.8% (95% CI, 20.8%–22.7%) had 
died, 22.6% (21.6%–23.6%) were alive but had stopped cART, 
14.8% (14.0%–15.6%) had transferred to another clinic, 9.2% 
(8.5%–9.8%) were considered as retained on cART, and 31.6% 
(30.6%–32.7%) could not be found.
The results of the subdistribution-specific hazard models for 
the different tracing outcomes are shown in Table 3. The inclu-
sion of an interaction term between gender and clinical stage fur-
ther improved the fit of the models for the mortality outcome. 
Mortality was associated with male sex, lower CD4 count, and 
more advanced clinical stage at cART initiation. Mortality was 
also associated with shorter duration on cART at the time of 
the last clinic visit, older age, and a last clinic visit before 2009. 
Stopping cART was associated with higher CD4 count, less ad-
vanced clinical stage, and longer duration on cART. Silent transfer 
to another clinic was associated with female sex, less advanced 
clinical stage, and a more recent last visit (2009 or later). Finding 
patients alive and on cART in the program was associated with 
higher CD4 counts, less advanced clinical stage, last visit before 
2009, longer time on cART, and adult age. The results from the 
complete case analysis, without imputation of missing CD4 cell 
counts, WHO clinical stage, age, and time on cART at LTFU were 
similar (Supplementary Table 1). When excluding the large study 
from Lilongwe, Malawi [25], results were similar to the main 
analysis (Supplementary Tables 2 and 3).
The 7 published studies that provided IPD were broadly rep-
resentative of all published studies: the 3 regions East Africa, 
Southern Africa, and Central Africa were represented, and in-
cluded and excluded studies were similar in their sex and age 
distributions and study periods. Included studies all conducted 
home visits for tracing patients and were done in urban settings, 
whereas some excluded studies used telephone tracing only, and 
a few excluded studies were from rural settings (Supplementary 
Table 4). Of note, the 7 studies contributed 7377 patients, which 
corresponds to 55.9% of the 13 200 patients included in the 24 
published studies. The comparison of the published aggregate 
data showed that there was little evidence for a difference in 
mortality, transfer to another clinic, and stop of cART between 
the included studies compared with the excluded ones (OR, 
0.62 [95% CI, .29–1.33]; OR, 1.04 [95% CI, .29–1.33]; and OR, 
1.59 [95% CI, .80–3.19], respectively).
Two cohorts [25, 27] from Malawi and Mozambique pro-
vided data on both patients retained in care (n = 18 285) and 
patients LTFU (n  =  5152). For those cohorts, the cumulative 
probability of death 4  years after the start of cART was esti-
mated to be >6 times higher among LTFU patients compared to 
patients retained in care: 20.6% (95% CI, 19.5%–21.7%) vs 3.3% 
(95% CI, 3.1%–3.6%) (Figure 3).Ta
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DISCUSSION
This collaborative study pooled individual-level data of almost 
7500 patients from 9 antiretroviral treatment programs in 8 
African countries to estimate mortality and other outcomes in 
patients LTFU. The results show that 4 years after the last clinic 
visit, about one-fifth of patients LTFU had died, a similar propor-
tion had stopped treatment, one-sixth had silently transferred to 
another clinic, and about one-third were not found. As expected, 
patients were more likely to remain LTFU as the delay between 
LFTU and tracing increased. Mortality was associated with male 
sex and more advanced disease, silent transfer with female sex and 
less advanced disease, and stopping therapy with less advanced 
disease. Death, stopping cART, and unsuccessful tracing were all 
associated with shorter duration of cART at the time of LTFU.
The analysis of IPD is an important strength of our study, 
which made it possible to estimate the association of patient 
characteristics on clinical outcomes, including the CD4 cell 
count and WHO clinical stage at cART initiation, and the 
duration on cART before patients became LTFU. Such IPD 
meta-analyses have been described as the “yardstick” against 
which the quality of other reviews should be judged [44, 45]. 
Advantages of IPD meta-analyses include the possibility of con-
ducting time to event analyses, harmonizing definitions and 
time points, but also the prevention of ecological bias where 
associations at the aggregate level do not reflect those at the 
individual level [46, 47]. Furthermore, the active involvement 
of investigators contributing data may enhance data quality, 
facilitate the provision of more recent data, and improve inter-
pretation of results. Indeed, several datasets provided for this 
analysis were updated to include more patients, and the authors 
of the 9 studies [12–14, 21–25, 27, 42, 43] all contributed to this 
project. Another strength of this study was the comprehensive 
literature search, which covered several bibliographic databases 
and recent major conferences [11].
IPD meta-analyses also have disadvantages. IPD are obtained 
typically only from a proportion of all eligible studies. Selection 
bias is therefore possible if the studies contributing data are not 
representative of all studies. We addressed this issue by com-
paring the 7 published articles that were included in this analy-
sis with the 15 that were excluded. We found that the included 
studies contributed more than half of all patients included in 
the published reports. Also, the characteristics of patients from 
included and excluded studies were similar, although CD4 cell 
count and clinical stage were not reported consistently in the 
published studies [11]. Finally, mortality and other tracing out-
comes were similar among included and excluded studies.
Our analysis took the competing risks of death and other 
tracing outcomes into account. For example, patients who died 
could no longer transfer to another treatment program, and 
patients who transferred could not be recorded as a death in 
the clinic where cART was initiated. In standard Kaplan-Meier 
analyses, the follow-up time of those developing a competing 
event is simply censored, assuming that the probability of the 
outcome of interest is the same as that of comparable patients 
remaining under observation [48]. This assumption is invalid 
because the outcome of interest can no longer occur in those 
with the competing event. An analysis of mortality in HIV-
infected patients on cART followed up in Zambia showed that 
the competing risk of death can substantially bias standard 
Kaplan-Meier life-table analyses of LFTU [49].
Figure 2. Cumulative incidence plot of the outcomes in patients lost to follow-up (LTFU), including death, stop of combination antiretroviral therapy (cART), transfer to an-
other clinic, and retention on cART. Cumulative probabilities, together with 95% confidence intervals, are given for each tracing outcome at 1–4 years since the last clinic visit.
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Our competing risk modeling approach accounted for 
between-study heterogeneity, including heterogeneity in study 
settings and size, by allowing for cohort-specific baseline haz-
ards. Of note, between-study heterogeneity in baseline hazards 
also did not materially influence estimates of the cumulative 
incidence of the different outcomes. In particular, results were 
similar when excluding the large study by Tweya et  al [25], 
which contributed 61.8% of all patients. This study, despite 
operating in a relatively well-resourced urban setting, can be 
assimilated to a real-world healthcare setting with routine data 
collection.
Silent transfers have increased with the scaling up of cART, 
likely due to the expansion of cART access and the availability 
of clinics nearer to patients’ home [11, 50]. We found that about 
15% of patients who were LTFU in the clinic where they started 
cART transferred to another facility within 4 years. Retention in 
care is therefore underestimated in analyses of individual clinics 
or programs [51]. Clearly, improving communication between 
the clinics and programs, for example, through a national cART 
database and unique patient identifiers [52], is urgently needed 
for an accurate assessment of overall retention in care. On the 
other hand, we confirm the much higher risk of death among 
patients LTFU compared to those retained in care, and the fact 
that estimates of mortality that are based on patients in care and 
under observation through a single facility data system will un-
derestimate mortality at the level of the program, that is, among 
all patients who started therapy [8, 9, 52].
The ratio of mortality between patients lost and not LTFU 
observed in our study for 2 treatment programs in Malawi [25] 
and Mozambique [27] can be directly used to correct mor-
tality estimates for LTFU, based on the fact that mortality of 
all patients starting cART in a treatment program is a weighted 
average of mortality among patients lost and patients re-
maining in care [8]. In general, the risk factors for mortality 
identified in our study will be useful to refine methods to cor-
rect mortality for LTFU, for example by taking the lower risk 
of death in women, the association with the CD4 cell count 
and clinical stage at the start of cART, or the duration of cART 
at LTFU into account. Indeed, within the framework of the 
HIV Measurement & Surveillance of HIV Epidemics (MeSH) 
Table 3. Subdistribution Hazard Ratios for Tracing Outcomes Death, Stop of Combination Antiretroviral Therapy (cART), Silent Transfer, and Retention on cART
Characteristic
Death Stop of cART Silent Transfer Retained on cART
SHR (95% CI) SHR (95% CI) SHR (95% CI) SHR (95% CI)
Sex
 Male 1 1 1 1
 Female 0.62 (.44–.88) 0.97 (.87–1.07) 1.32 (1.17–1.50) 1.03 (.90–1.18)
CD4 counta (cells/µL)
 <50 1 1 1 1
 50–99 0.75 (.64–.88) 1.52 (1.21–1.90) 1.13 (.86–1.49) 0.88 (.66–1.19)
 ≥100 0.40 (.35–.45) 1.77 (1.47–2.13) 1.17 (.93–1.47) 1.47 (1.17–1.84)
WHO clinical stagea
 I–II 1 1 1 1
 III 1.23 (.93–1.63) 0.77 (.64–.91) 0.88 (.71–1.09) 0.77 (.60–1.00)
 IV 1.57 (1.17–2.10) 0.64 (.51–.80) 0.71 (.56–.91) 0.71 (.53–.95)
Last clinic visit
 Before 2009 1 1 1 1
 2009 or later 0.76 (.66–.87) 1.04 (.92–1.18) 1.56 (1.36–1.80) 0.33 (.27–.40)
Ageb (y)
 <16 1 1 1 1
 16–29 1.73 (.92–3.25) 0.99 (.70–1.39) 0.71 (.35–1.45) 1.68 (1.00–2.82)
 30–39 2.21 (1.18–4.15) 0.89 (.63–1.25) 0.84 (.41–1.72) 1.79 (1.04–3.08)
 ≥40 2.84 (1.52–5.32) 0.75 (.53–1.06) 0.91 (.45–1.87) 1.79 (1.04–3.09)
Time on cARTb (y)
 <1 1 1 1 1
 1–2 0.51 (.44–.60) 1.28 (1.13–1.45) 1.02 (.87–1.20) 1.89 (1.62–2.21)
 ≥2 0.44 (.36–.53) 1.14 (1.00–1.30) 1.05 (.87–1.28) 1.94 (1.60–2.37)
Interactiona
 Female clinical stage I–II 1
 Female clinical stage III 1.32 (.91–1.92)
 Female clinical stage IV 1.73 (1.17–2.56)
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; SHR, subdistribution hazard ratio; WHO, World Health Organization.
aAt cART initiation.
bAt last clinic visit. All models are stratified by cohort. Parameter estimates are pooled estimates from models fitted to 20 imputed datasets. Each model is fitted for the tracing outcome of 
interest, accounting for the alternative outcomes as competing risks.
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy347/5034717
by Liverpool School of Tropical Medicine user
on 18 June 2018
8 • CID 2018:XX (XX XXXX) • Chammartin et al
Consortium, we will be working on improving existing meth-
ods [14] and developing new applications, based on the find-
ings of the present study.
The risk factors for death identified in this study are directly 
relevant to HIV care and treatment programs in sub-Saharan 
Africa. For example, time on cART at the time of LTFU was 
an important determinant of the mortality risk among patients 
LTFU. We showed that patients who initiated cART <1  year 
prior to being lost were at higher mortality risk. These patients, 
with low CD4 counts or advanced clinical stage, should there-
fore be prioritized for tracing, with stricter definitions for LTFU 
to trigger early action, so that they can be supported to re-
main in care and on cART as soon as possible. Furthermore, 
tracing should start soon after LTFU to reduce mortality, and 
the number of patients who are not found.
To conclude, our study showed that mortality and undo-
cumented transfer were substantial among LTFU patients in 
sub-Saharan Africa. The results are useful to predict clinical 
outcomes in patients LTFU, and to assess program effective-
ness, with less biased estimates of retention and mortality. We 
acknowledge that our results may not be generalizable to many 
settings in sub-Saharan Africa, and we recommend that cART 
programs trace patients LTFU and use results to estimate pro-
gram-level outcomes. Indeed, to further improve our under-
standing of LTFU and the outcomes of patients LTFU, we are 
planning tracing studies using standardized methods and data 
Figure 3. Cumulative incidence plot of outcomes for 5152 patients lost to follow-up (LTFU) after starting combination antiretroviral therapy (cART) (A) and 18 285 patients 
retained in care (B) in 2 treatment programs in Malawi and Mozambique. Cumulative probabilities, together with 95% confidence intervals, are given for each outcome at 
1–4 years after cART initiation.
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collection within the framework of the International epide-
miology Databases to Evaluate AIDS (IeDEA) [53], including 
studies in South Africa where mortality of patients not found 
by tracing can be ascertained trough linkage with the civil 
registry [52].
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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